Rituximab for Immune Cytopenia in Adults: Idiopathic Thrombocytopenic Purpura, Autoimmune Hemolytic Anemia, and Evans Syndrome

Mayo Clinic Proceedings

Volumn 78, Issue 11, 2003, Pages 1340-1346

  Shanafelt, Tait D ^a   Madueme, Hans L ^a   Wolf, Robert C ^a   Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DANAZOL; DEXAMETHASONE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; AUTOIMMUNE HEMOLYTIC ANEMIA; BLOOD CELL COUNT; CLINICAL ARTICLE; COMORBIDITY; CYTOPENIA; DRUG EFFICACY; FEMALE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MALE; MEDICAL RECORD; REMISSION; RETROSPECTIVE STUDY; REVIEW; SPLENECTOMY;

EID: 0242318191     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/78.11.1340     Document Type: Article

References (41)

1. Provan D, Newland A. Fifty years of idiopathic thrombocytopenic purpura (ITP): management of refractory itp in adults. Br J Haematol. 2002;118:933-944.
2. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002;346:995-1008.
3. Gehrs BC, Friedberg RC. Autoimmune hemolytic anemia. Am J Hematol. 2002;69:258-271.
4. Kumar S, Diehn FE, Gertz MA, Tefferi A. Splenectomy for immune thrombocytopenic purpura: long-term results and treatment of postsplenectomy relapses. Ann Hematol. 2002;81:312-319.
5. Sallah S, Wan JY, Hanrahan LR. Future development of lymphoproliferative disorders in patients with autoimmune hemolytic anemia. Clin Cancer Res. 2001;7:791-794.
6. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997;90:2188-2195.
7. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825-2833.
8. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998;92:1927-1932.
9. Hainsworth JD, Burris HA III, Morrissey LH, et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood. 2000;95:3052-3056.
10. Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol. 2001;19:2153-2164.
11. Huhn D, von Schilling C, Wilhelm M, et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood. 2001;98:1326-1331.
12. Liebman HA. Expanding use of rituximab in immunopathic disorders. Blood. 2003;101:3759-3760.
13. Saleh MN, Gutheil J, Moore M, et al. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. Semin Oncol. 2000;27(6, suppl 12):99-103.
14. Quartier P, Brethon B, Philippet P, Landman-Parker J, Le Deist F, Fischer A. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet. 2001;358:1511-1513.
15. Zecca M, De Stefano P, Nobili B, Locatelli F. Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia. Blood. 2001;97:3995-3997.
16. Giagounidis AA, Anhuf J, Schneider P, et al. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study. Eur J Haematol. 2002;69:95-100.
17. Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood. 2001;98:952-957.
18. Stasi R, Stipa E, Forte V, Meo P, Amadori S. Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura. Blood. 2002;99:3872-3873.
19. Zecca M, Nobili B, Ramenghi U, et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood. 2003;101:3857-3861.
20. Lee EJ, Kueck B. Rituxan in the treatment of cold agglutinin disease [letter]. Blood. 1998;92:3490-3491.
21. Bauduer F. Rituximab: a very efficient therapy in cold agglutinins and refractory autoimmune haemolytic anaemia associated with CD20-positive, low-grade non-Hodgkin's lymphoma [letter]. Br J Haematol. 2001;112:1085-1086.
22. Cohen Y, Polliack A, Zelig O, Goldfarb A. Monotherapy with rituximab induces rapid remission of recurrent cold agglutinin-mediated hemolytic anemia in a patient with indolent lymphoplasmacytic lymphoma. Leuk Lymphoma. 2001;42:1405-1408.
23. Iannitto E, Ammatuna E, Marino C, Cirrincione S, Greco G, Mariani G. Sustained response of refractory chronic lymphocytic leukemia in progression complicated by acute hemolitic anemia to anti-CD20 monoclonal antibody [letter]. Blood. 2002;99:1096-1097.
24. Gupta N, Kavuru S, Patel D, et al. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia. 2002;16:2092-2095.
25. Hegde UP, Wilson WH, White T, Cheson BD. Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia. Blood. 2002;100:2260-2262.
26. Chemnitz J, Draube A, Diehl V, Wolf J. Successful treatment of steroid and cyclophosphamide-resistant hemolysis in chronic lymphocytic leukemia with rituximab [letter]. Am J Hematol. 2002;69:232-233.
27. Trape G, Fianchi L, Lai M, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for refractory hemolytic anemia in patients with lymphoproliferative disorders. Haematologica. 2003;88:223-225.
28. Zaja F, Iacona I, Masolini P, et al. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia [published correction appears in Haematologica. 2002;87:336]. Haematologica. 2002;87:189-195.
29. Zaja F, Iacona I, Masolini P, et al. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia [published correction appears in Haematologica. 2002;87:336]. Haematologica. 2002;87:189-195.
30. Seipelt G, Bohme A, Koschmieder S, Hoelzer D. Effective treatment with rituximab in a patient with refractory prolymphocytoid transformed B-chronic lymphocytic leukemia and Evans syndrome. Ann Hematol. 2001;80:170-173.
31. Abdel-Raheem MM, Potti A, Kobrinsky N. Severe Evans's syndrome secondary to interleukin-2 therapy: treatment with chimeric monoclonal anti-CD20 antibody. Ann Hematol. 2001;80:543-545.
32. Bourgeois E, Caulier MT, Delarozee C, Brouillard M, Bauters F, Fenaux P. Long-term follow-up of chronic autoimmune thrombocytopenic purpura refractory to splenectomy: a prospective analysis. Br J Haematol. 2003;120:1079-1088.
33. Emilia G, Morselli M, Luppi M, et al. Long-term salvage therapy with cyclosporin A in refractory idiopathic thrombocytopenic purpura. Blood. 2002;99:1482-1485.
34. Kappers-Klunne MC, van't Veer MB. Cyclosporin A for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids or splenectomy. Br J Haematol. 2001;114:121-125.
35. Howard J, Hoffbrand AV, Prentice HG, Mehta A. Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anaemia and auto-immune thrombocytopenia purpura. Br J Haematol. 2002;117:712-715.
36. Willis F, Marsh JC, Bevan DH, et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol. 2001;114:891-898.
37. Huhn RD, Fogarty PF, Nakamura R, et al. High-dose cyclophosphamide with autologous lymphocyte-depleted peripheral blood stem cell (PBSC) support for treatment of refractory chronic autoimmune thrombocytopenia. Blood. 2003;101:71-77.
38. Zaydan MA, Turner C, Miller AM. Resolution of chronic idiopathic thrombocytopenia purpura following syngeneic peripheral blood progenitor transplant. Bone Marrow Transplant. 2002;29:87-89.
39. Oyama Y, Papadopoulos EB, Miranda M, Traynor AE, Burt RK. Allogeneic stem cell transplantation for Evans syndrome. Bone Marrow Transplant. 2001;28:903-905.
40. Cohen Y, Polliack A. Sustained complete remission of chronic refractory immune thrombocytopenic purpura (ITP) of 10 years duration after only two infusions of rituximab [letter]. Hematol J. 2002;3:61-62.
41. Diz-Kucukkaya R, Hacihanefioglu A, Yenerel M, et al. Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study. Blood. 2001;98:1760-1764.